Last reviewed · How we verify
Sulperazon
At a glance
| Generic name | Sulperazon |
|---|---|
| Also known as | Tinidazole injection |
| Sponsor | Tongji Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients (NA)
- Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application
- Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy (NA)
- Establishment of Risk Factors Model of Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium
- Prevention of Cefoperazone-induced Coagulopathy (PHASE4)
- Evaluate Bioequivalence of Burotam (1/1 g/Vial) (PHASE4)
- Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy (PHASE4)
- Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulperazon CI brief — competitive landscape report
- Sulperazon updates RSS · CI watch RSS
- Tongji Hospital portfolio CI